These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 25816315

  • 21. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 22. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S, Lee LA, Sule N, Fowler A, Peachey G.
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [Abstract] [Full Text] [Related]

  • 23. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
    Mehta R, Kelleher D, Preece A, Hughes S, Crater G.
    Int J Chron Obstruct Pulmon Dis; 2013 Jul; 8():159-67. PubMed ID: 23569370
    [Abstract] [Full Text] [Related]

  • 24. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
    Nakahara N, Wakamatsu A, Kempsford R, Allen A, Yamada M, Nohda S, Hirama T.
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
    Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A.
    Respir Med; 2014 Dec; 108(12):1752-60. PubMed ID: 25458157
    [Abstract] [Full Text] [Related]

  • 26. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
    Yang S, Lee L, Mallett S, Ayer J, Wolstenholme A, Pascoe S.
    Adv Ther; 2015 Feb; 32(2):157-71. PubMed ID: 25700806
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

  • 30. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
    Condreay L, Huang L, Harris E, Brooks J, Riley JH, Church A, Ghosh S.
    Respir Med; 2016 May; 114():123-6. PubMed ID: 27109822
    [Abstract] [Full Text] [Related]

  • 31. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
    Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH.
    Int J Chron Obstruct Pulmon Dis; 2018 May; 13():203-215. PubMed ID: 29386889
    [Abstract] [Full Text] [Related]

  • 32. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
    Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Wise RA, Singh D, Martinez FJ.
    Am J Respir Crit Care Med; 2020 Nov 01; 202(9):1237-1243. PubMed ID: 32584168
    [Abstract] [Full Text] [Related]

  • 33. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X, Zheng X, Jiang J, Hu P, Wu K, Zhuang L, Liu L, Du X, Kempsford R, Allen A.
    Pharmacotherapy; 2015 Jun 01; 35(6):586-99. PubMed ID: 26059225
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
    Kempsford R, Allen A, Bareille P, Hamilton M, Cheesbrough A.
    Clin Pharmacol Drug Dev; 2015 Jan 01; 4(1):2-11. PubMed ID: 27127998
    [Abstract] [Full Text] [Related]

  • 37. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
    Ramadan WH, Al Masri S, Rizk J.
    Clin Respir J; 2019 Nov 01; 13(11):663-673. PubMed ID: 31389190
    [Abstract] [Full Text] [Related]

  • 38. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
    Cahn A, Tal-Singer R, Pouliquen IJ, Mehta R, Preece A, Hardes K, Crater G, Deans A.
    Clin Drug Investig; 2013 Jul 01; 33(7):477-88. PubMed ID: 23784369
    [Abstract] [Full Text] [Related]

  • 39. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
    Kempsford R, Allen A, Kelly K, Saggu P, Crim C.
    Br J Clin Pharmacol; 2014 Mar 01; 77(3):466-79. PubMed ID: 24093504
    [Abstract] [Full Text] [Related]

  • 40. The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.
    Requena G, Dedman D, Quint JK, Ghosh RE, Williams R, Pimenta JM.
    Int J Chron Obstruct Pulmon Dis; 2021 Mar 01; 16():629-642. PubMed ID: 33731992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.